Patient organizations for those with inflammatory bowel disease (IBD) are upset with the government of British Columbia for a plan to shift patients to biosimilars over the next 6 months.
Patient organizations for those with inflammatory bowel disease (IBD) are upset with the government of British Columbia for a plan to shift patients to biosimilars over the next 6 months.
As announced by the province last week, patients with Crohn disease (CD) and ulcerative colitis (UC) will have 6 months to move from reference infliximab (Remicade) to either of the infliximab biosimilars, Inflectra and Renflexis. After March 5, 2020, PharmaCare, a publicly funded drug coverage program, will stop coverage for Remicade for these indications, except in certain circumstances.
Earlier this year, British Columbia became the first Canadian province to mandate that patients currently taking reference biologics for rheumatology indications and for diabetes must be switched to biosimilars over a 6-month period.
Patients are opposed to the conceit of nonmedical switching, or moving patients off the reference product purely for financial or for formulary reasons.
“We believe the onus is on payers (government or private) to negotiate with manufacturers of innovative biologics and their biosimilars to protect options for patient care,” wrote Gail Attara, president and chief executive officer of the Gastrointestinal Society and president of the Canadian Society of Intestinal Research. “It is reasonable to expect that manufacturers should lower prices when drugs are no longer on patent.”
She also said IBD is a difficult condition to manage and switching someone without knowing the consequence could stir mental and emotional risk, including the nocebo effect. Attara also said that Canada has a different healthcare system than Europe, where different countries may have different payment systems and models that could influence biosimilar uptake.
Canada has a significantly lower use rate for biosimilars, at approximately 8%. Other European Union countries have upwards of 50% to 95%; Attara said the actual percentages vary based on the age of the biosimilar.
Separately, Crohn’s and Colitis Canada released an updated position statement on biosimilars; while noting that biosimilars are safe and effective, the organization said the “decision to switch a patient from a biologic drug to its biosimilar should be based on patient/doctor choice.”
It also released a survey of gastroenterologists, nurses, patients, and caregivers that showed just more than 50% of gastroenterologists and IBD nurses agreed that a 1-time switch for patients with IBD from a reference biologic to a biosimilar was acceptable.
Asked about the possibility of a switch, patients said they would need support, including additional and dedicated appointments with their specialists and nurses, education and communication, and financial information and support.
Crohn’s and Colitis Canada also said that if the price difference between the reference product and the originator is ever eliminated, policy makers should stop mandatory nonmedical switches.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.